EYEPOINT PHARMACEUTICALS INC (EYPT) Stock Price, Quote, News and Overview
NASDAQ:EYPT - Nasdaq - US30233G2093 - Common Stock - Currency: USD
EYPT Quote, Performance and Key Statistics
EYEPOINT PHARMACEUTICALS INC
NASDAQ:EYPT (2/5/2025, 7:00:19 PM)
After market: 7.77 -0.03 (-0.38%)7.8
+0.18 (+2.36%)
The current stock price of EYPT is 7.8 USD. In the past month the price decreased by -10.14%. In the past year, price decreased by -72.92%.
EYPT Latest News, Press Releases and Analysis
These stocks are moving in today's pre-market session
Let's have a look at what is happening on the US markets before the opening bell on Wednesday. Below you can find the top gainers and losers in today's pre-market session.
EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema Meeting Primary and Secondary Endpoints
- Primary endpoint achieved by both DURAVYU doses (1.34mg and 2.7mg) with extended time to first supplemental injection versus aflibercept control – -...
EyePoint to Present at Guggenheim SMID Cap Biotech Conference
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing...
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing...
EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors
WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing...
EYPT Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 82.81 | 799.50B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 29.06 | 380.66B | ||
| JNJ | JOHNSON & JOHNSON | 15.48 | 372.43B | ||
| MRK | MERCK & CO. INC. | 11.74 | 226.83B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.62 | 219.96B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.86 | 219.54B | ||
| PFE | PFIZER INC | 8.5 | 149.84B | ||
| SNY | SANOFI-ADR | 13.51 | 134.13B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 51.03 | 121.10B | ||
| ZTS | ZOETIS INC | 30.5 | 79.26B | ||
| GSK | GSK PLC-SPON ADR | 9.11 | 76.92B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.09 | 42.39B |
Related stock screener links
About EYPT
Company Profile
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. The company is headquartered in Watertown, Massachusetts and currently employs 121 full-time employees. The company went IPO on 2005-01-27. The firm is focused on the business of developing and commercializing ophthalmic products for the treatment of eye diseases. The firm's pipeline leverages its Durasert technology (Durasert) for sustained intraocular drug delivery, including delivery of EYP-1901, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases. Its additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. EYP-1901 is presently in Phase 2 clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), no proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The Company’s other products include YUTIQ, and DEXYCU.
Company Info
EYEPOINT PHARMACEUTICALS INC
480 Pleasant St Ste B300
Watertown MASSACHUSETTS 02472 US
CEO: Nancy Lurker
Employees: 121
Company Website: https://eyepointpharma.com/
Investor Relations: https://investors.eyepointpharma.com/
Phone: 16179265000
EYPT FAQ
What is the stock price of EYPT?
The current stock price of EYPT is 7.8 USD.
What is the symbol for EYEPOINT PHARMACEUTICALS INC stock?
The exchange symbol of EYEPOINT PHARMACEUTICALS INC is EYPT and it is listed on the Nasdaq exchange.
On which exchange is EYPT stock listed?
EYPT stock is listed on the Nasdaq exchange.
Is EYPT a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for EYPT, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of EYPT.
Does EYPT stock pay dividends?
EYPT does not pay a dividend.
When does EYPT stock report earnings?
EYPT will report earnings on 2025-02-27, after the market close.
What is the Price/Earnings (PE) ratio of EYPT?
EYPT does not have a PE ratio as the earnings reported over the last twelve months were negative (-2).
What is the Short Interest ratio of EYPT stock?
The outstanding short interest for EYPT is 16.3% of its float.
EYPT Technical Analysis
EYPT Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to EYPT. EYPT has a great financial health rating, but its profitability evaluates not so good.
EYPT Financial Highlights
Over the last trailing twelve months EYPT reported a non-GAAP Earnings per Share(EPS) of -2. The EPS decreased by 24.81% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -34.42% | ||
| ROE | -47.35% | ||
| Debt/Equity | 0 |
EYPT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to EYPT. The Buy consensus is the average rating of analysts ratings from 18 analysts.
For the next year, analysts expect an EPS growth of -26.2% and a revenue growth 6.2% for EYPT